macular polypoidal choroidal vasculopathy (PCV)
Showing 1 - 25 of 2,657
Macular Polypoidal Choroidal Vasculopathy (PCV) Trial in Korea, Republic of (Brolucizumab 6mg)
Not yet recruiting
- Macular Polypoidal Choroidal Vasculopathy (PCV)
- Brolucizumab 6mg
-
Busan, Korea, Republic of
- +13 more
Dec 19, 2022
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
Recruiting
- Polypoidal Choroidal Vasculopathy
- +2 more
- Intravitreal aflibercept injection
-
Seoul, Korea, Republic ofJae Hui Kim
Dec 20, 2022
Polypoidal Choroidal Vasculopathy Trial in Singapore (Aflibercept + reduced fluence photodynamic therapy (RF-PDT), Aflibercept +
Recruiting
- Polypoidal Choroidal Vasculopathy
- Aflibercept + reduced fluence photodynamic therapy (RF-PDT)
- Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT)
-
Singapore, Singapore
- +2 more
Nov 14, 2022
Symtomatic Macular Polypoidal Choroidal Vasculopathy Trial in Bangkok (Intravitreous aflibercept injection)
Completed
- Symtomatic Macular Polypoidal Choroidal Vasculopathy
- Intravitreous aflibercept injection
-
Bangkok, ThailandRajavithi Hospital
Oct 21, 2020
Polypoidal Choroidal Vasculopathy Trial in Peking (non-interventional)
Recruiting
- Polypoidal Choroidal Vasculopathy
- non-interventional
-
Peking, Beijing, ChinaPeking Union Medical College Hospital
Nov 28, 2022
Polypoidal Choroidal Vasculopathy, Conbercept Trial in Beijing (Conbercept)
Completed
- Polypoidal Choroidal Vasculopathy
- Conbercept
-
Beijing, ChinaPeking Union Medical College Hospital
Feb 7, 2022
Age Related Macular Degeneration, Polypoidal Choroidal Vasculopathy Trial in Singapore (Treat and Extend with Aflibercept 2mg,
Completed
- Age Related Macular Degeneration
- Polypoidal Choroidal Vasculopathy
- Treat and Extend with Aflibercept 2mg
- Fixed Dosing with Aflibercept 2mg
-
Singapore, Singpore, SingaporeSingapore National Eye Centre
Aug 17, 2021
Needs in Polypoidal Choroidal Vasculopathy (PCV)
Recruiting
- Polypoidal Choroidal Vasculopathy
- Indocyanine Green Angiography
-
Singapore, Singapore
- +2 more
Sep 27, 2021
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy Trial (Episcleral Brachytherapy, Aflibercept Injection)
Not yet recruiting
- Age-Related Macular Degeneration
- Polypoid Choroidal Vasculopathy
- Episcleral Brachytherapy
- Aflibercept Injection
- (no location specified)
Feb 21, 2022
Polypoidal Choroidal Vasculopathy Trial in Chiang Mai (Aflibercept Injection (2 mg/0.05 ml), Defer treatment)
Recruiting
- Polypoidal Choroidal Vasculopathy
- Aflibercept Injection (2 mg/0.05 ml)
- Defer treatment
-
Chiang Mai, ThailandVoraporn Chaikitmongkol
Jan 13, 2021
OCTA and Polypoidal Choroidal Vasculopathy
Completed
- Polypoidal Choroidal Vasculopathy
- Ranibizumab Injection
-
Naples, ItalyUniversity of Naples "Federico II"
Jan 14, 2021
Pachychoroid Neovasculopathy Trial (Three monthly injections of intravitreal aflibercept)
Not yet recruiting
- Pachychoroid Neovasculopathy
- Three monthly injections of intravitreal aflibercept
- (no location specified)
Dec 14, 2022
Neovascular Macular Degeneration Trial in Worldwide (Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne)
Completed
- Neovascular Macular Degeneration
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Visudyne
-
Liverpool, New South Wales, Australia
- +61 more
Nov 17, 2020
Central Serous Chorioretinopathy, Age Related Macular Degeneration, Idiopathic Poplypoidal Choroidal Vasculopathy Trial in
Recruiting
- Central Serous Chorioretinopathy
- +2 more
-
Toronto, Ontario, CanadaSunnybrook Research Institute
Jan 25, 2021
OCT in Rare Chorioretinal Diseases
Recruiting
- Retinal Artery Occlusions
- +4 more
-
Portland, OregonCasey Eye Institute, Oregon Health & Science University
Jul 13, 2021
Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy Trial in Yangsan, Busan (ranibizumab)
Unknown status
- Exudative Age-related Macular Degeneration
- Polypoidal Choroidal Vasculopathy
-
Yangsan, Gyeongsangnam-do, Korea, Republic of
- +1 more
Oct 8, 2019
Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy Trial in Worldwide (Ranibizumab, Verteporfin PDT, Sham PDT)
Completed
- Age-related Macular Degeneration
- Polypoidal Choroidal Vasculopathy
- Ranibizumab
- +2 more
-
Hong Kong, Hong Kong
- +41 more
Mar 5, 2019
Polypoidal Choroidal Vasculopathy Trial in Portugal, Spain (Intravitreal Aflibercept)
Completed
- Polypoidal Choroidal Vasculopathy
- Intravitreal Aflibercept
-
Braga, Portugal
- +12 more
Jan 8, 2020
Polypoidal Choroidal Vasculopathy Trial in China (Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose)
Terminated
- Polypoidal Choroidal Vasculopathy
- Lucentis® (Raibizumab) double-dose
- Lucentis® (Raibizumab) regular-dose
-
Guangzhou, Guangdong, China
- +3 more
Sep 17, 2019
Choroidal Neovascularization, Choroid Disease Trial in Palermo (Aflibercept Injection)
Completed
- Choroidal Neovascularization
- Choroid Disease
- Aflibercept Injection
-
Palermo, ItalyAzienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Aug 30, 2019
Polypoidal Choroidal Vasculopathy Trial in Shanghai, Hangzhou, Wenzhou (conbercept, Initial PDT, Delayed PDT)
Completed
- Polypoidal Choroidal Vasculopathy
- conbercept
- +2 more
-
Shanghai, Shanghai, China
- +2 more
Jul 17, 2019
Biomarkers of Common Eye Diseases
Unknown status
- Uveitis
- +5 more
- Collection of blood samples
-
Guangzhou, Guangdong, ChinaZhognshan Ophthalmic Center, Sun Yat-sen University
Sep 25, 2019
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion With Macular Edema Trial in Makati
Completed
- Neovascular Age-related Macular Degeneration
- +4 more
- Intravitreal injection guide (Malosa)
- Dual Blade Eyelid Speculum
-
Makati City, MM, PhilippinesPeregrine Eye and Laser Instittute
Apr 25, 2021
Polypoidal Choroidal Vasculopathy Trial in Augusta (ranibizumab 0.5 or 0.3 mg/0.05 cc)
Completed
- Polypoidal Choroidal Vasculopathy
- ranibizumab 0.5 or 0.3 mg/0.05 cc
-
Augusta, GeorgiaSoutheast Retina Center
Apr 8, 2019
Wet Age-related Macular Degeneration Trial (SCB-420, Aflibercept)
Withdrawn
- Wet Age-related Macular Degeneration
- (no location specified)
Apr 12, 2022